Voltaren forte(+Codeine)

Method of action: Nonsteroidal Anti-Inflammatory

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Voltaren forte(+Codeine)

Property	Description
Active ingredients	Diclofenac and Codeine
Form	Tablet
Pharmacological class	NSAID and Opioid Analgesic Combination
Route of administration	Oral route
Origin	Mixed (Synthetic and Semi-synthetic)
Type	Prescription-only Combination drug

What Type of Medicine is Voltaren forte (+Codeine)?

Voltaren forte (+Codeine) is defined as a prescription-only combination drug administered via the oral route in a tablet dosage form. This preparation belongs to two key pharmacological classes concurrently: the Nonsteroidal Anti-Inflammatory Drug (NSAID) class and the Opioid Analgesic Combination class. The formulation is characterized as a combination designed for enhanced pain reduction. The Diclofenac component is a synthetic chemical compound, while Codeine is a semi-synthetic compound derived from the opium poppy, defining the product's mixed origin.

Diclofenac and Codeine: A Combination of Active Ingredients

The medicinal effect is achieved by the combined action of the two core active ingredients—Diclofenac and Codeine—utilized as their pharmaceutical salts. Diclofenac functions as a peripheral anti-inflammatory agent, which limits the synthesis of inflammatory chemicals known as prostaglandins. Conversely, Codeine acts as a central analgesic, targeting the central nervous system to alter the patient's perception of discomfort. This strategic blend creates a synergistic analgesic effect intended to provide relief when single-agent treatments are insufficient. This combination product is designed for adults, combining anti-inflammatory action with centralized pain modulation.

The General Purpose of This Dual-Action Analgesic

The general purpose of the Voltaren forte (+Codeine) preparation is to provide management for pain that is severe and often includes an underlying inflammation component, such as severe musculoskeletal discomfort. The formulation is intended to provide relief for episodes of moderate to severe acute pain or to manage aspects of persistent chronic pain where a single-mechanism drug would be inadequate for effective patient management. This clinical approach leverages the NSAID component to address the cause of inflammation while the Opioid Analgesic component provides central pain relief.

Regulatory References

Diclofenac: MedlinePlus Drug Information

What side effects are possible with Voltaren forte(+Codeine)?

Possible Side Effects and Safety Information

The official safety documentation for Voltaren forte (+Codeine) (Diclofenac and Codeine) organizes potential health risks based on frequency of occurrence and the body system affected. All adverse reactions are classified using a regulatory frequency framework (e.g., very common, common, rare, very rare).

Commonly Documented Adverse Reactions

Adverse reactions that are frequently reported, typically categorized under Common or Very Common, often involve the gastrointestinal and nervous systems. These may include headache, dizziness, nausea, vomiting, diarrhea, indigestion, and abdominal pain. Codeine, an opioid component, is also commonly associated with constipation and somnolence (drowsiness).

Serious Adverse Reactions and Safety Limitations

The most serious safety concerns for this combination product relate to the Diclofenac (NSAID) and Codeine (opioid) components:

Serious Gastrointestinal Events: Diclofenac is associated with a risk of gastrointestinal bleeding, ulceration, or perforation, which can be fatal. This risk increases with higher doses and longer duration of use.
Cardiovascular Thrombotic Events: Serious and potentially fatal events such as myocardial infarction (heart attack) and stroke have been reported with NSAID use, and the risk may increase with dose and duration.
Respiratory Depression: Codeine use carries a risk of life-threatening respiratory depression, particularly in individuals who are ultra-rapid metabolizers of the drug.
Hepatotoxicity and Serious Skin Reactions: Diclofenac can cause liver enzyme elevations and, in rare cases, serious hepatic reactions (e.g., hepatitis) and severe skin reactions (e.g., Stevens-Johnson syndrome).

Safety Restrictions and Contraindications

The medicine is strictly contraindicated (prohibited) in patients with conditions that pose an unacceptable risk. These include active gastrointestinal bleeding or ulceration, severe heart failure, severe liver or kidney failure, and the last trimester of pregnancy. Due to the codeine component, the medicine is also contraindicated in all children under 12 years of age and in individuals known to be ultra-rapid CYP2D6 metabolizers.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for this combination reflects the distinct toxicities of both Diclofenac and Codeine, with regulatory documents classifying an overdose as potentially life-threatening or fatal.

Documented Manifestations and Severe Outcomes

Overdose manifestations of the opioid component (Codeine) may include profound sedation, extreme sleepiness, confusion, and loss of consciousness. The most severe risk documented is slow and shallow breathing or apnea, which can lead to respiratory failure and circulatory collapse. The NSAID component (Diclofenac) may present with nausea, vomiting (potentially bloody), epigastric pain, and in very severe cases, seizures. Documented severe outcomes include gastrointestinal perforation, acute renal failure, and hepatic necrosis.

Required Emergency Actions

Regulators mandate that patients seek medical attention immediately or contact emergency services for any suspected overdose or the appearance of severe symptoms such as unusual sleepiness or difficulty breathing. Naloxone is documented as the agent used to reverse the life-threatening effects of the opioid component; however, no specific antidote is known for Diclofenac toxicity, requiring management to be symptomatic and supportive.

Official warnings state that accidental ingestion of even one dose can result in a fatal overdose in children, and the product is contraindicated for all children younger than 12 years.

Therapeutic Uses of Voltaren forte(+Codeine)

What Voltaren forte (+Codeine) Treats: Main Uses and Benefits

Voltaren forte (+Codeine) is commonly used in adults to provide supportive management of pain that is classified as moderate to severe, particularly where inflammation is a contributing factor. The combination is applied across domains where additional symptomatic support may be needed.

Focused Symptomatic Relief

This combination is considered relevant in clinical settings marked by heightened patient distress arising from severe musculoskeletal and inflammatory disorders. It is commonly used for conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as intense forms of back pain and sciatica. It is commonly used to help with pronounced symptoms that may become intense or disruptive, including joint pain, associated swelling, and stiffness, and may assist with maintaining a sense of stability when symptoms are more noticeable during symptomatic periods.

The medication is also applied in contexts where additional symptomatic support may be appropriate, such as in cases of post-operative pain following surgical procedures or significant pain after physical trauma. It is also relevant for managing symptoms linked to inflammatory or irritative states, such as episodes of gout or pronounced menstrual cramps.

The application of this medication is aligned with contexts involving heightened symptom expression, supporting general well-being during symptomatic phases.

“The application of this medication is aligned with contexts involving heightened symptom expression, supporting general well-being during symptomatic phases.”

Quick Fact: Relief for Moderate to Severe Pain

This combination is relevant in contexts where symptoms that interfere with daily functioning are present, providing support that contributes to easing the overall symptom load during acute or episodic manifestations.

Regulatory References

NIH StatPearls Overview of Diclofenac Indications

Eligibility and Restrictions for Use

The eligibility profile for Voltaren forte (+Codeine) is strictly defined by regulatory documents governing its dual active ingredients, Diclofenac and Codeine. The medicine is intended primarily for adults who are free of specific pre-existing conditions.

Use is contraindicated in several groups due to the opioid component. This includes all breastfeeding women, patients of any age known to be CYP2D6 ultra-rapid metabolisers, and all children under 12 years of age. Furthermore, adolescents are prohibited from using the drug after tonsillectomy or adenoidectomy for obstructive sleep apnoea.

The NSAID component imposes further exclusions. The medicine is contraindicated for individuals with severe heart failure, established Ischaemic Heart Disease, and active gastrointestinal ulceration or bleeding. It is also prohibited during the last trimester of pregnancy.

Use is conditional and subject to careful consideration for patients with cardiovascular risk factors (such as hypertension or diabetes) and those with severe hepatic or renal impairment.

What should I know about interactions with other medicines?

This combination product contains diclofenac (an NSAID) and codeine (an opioid), and its interaction profile is defined by both components.

Diclofenac (NSAID) Interactions

Co-administration with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of aspirin, is not generally recommended due to an increased risk of serious gastrointestinal adverse events, such as bleeding and ulceration. The risk of bleeding is also increased when diclofenac is used with anticoagulants (e.g., warfarin), SSRI/SNRI antidepressants, and other antiplatelet agents.

Diclofenac may diminish the antihypertensive effect of ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and diuretics. Concurrent use with ACE inhibitors or ARBs may also lead to deterioration of kidney function, especially in the elderly, volume-depleted patients, or those with renal impairment. Diclofenac can also increase the serum concentration of digoxin.

Codeine (Opioid) Interactions

Concomitant use of codeine with other Central Nervous System (CNS) depressants, including alcohol and benzodiazepines, poses a risk of profound sedation, respiratory depression, coma, and death. If the combination is necessary, use must be limited to the minimum effective dose and shortest duration. Codeine is subject to further population-specific constraints; for example, it is restricted or contraindicated in certain pediatric and adolescent groups due to the risk of life-threatening respiratory depression.

Mechanism of Action

Modulating Prostaglandin Synthesis at the Molecular Level

This domain covers the action of Diclofenac, which reversibly inhibits the Cyclooxygenase (COX) enzymes, primarily COX-1 and COX-2. This suppression leads to a decrease in the biosynthesis of prostaglandins, which are critical local mediators. The physiological consequence of this inhibition is the attenuation of localized nociceptive signal propagation and decreased synthesis of local inflammatory mediators at the site of tissue damage.

Central Opioid Receptor Engagement

This cluster explains the action of Codeine, which is metabolized into its active form, and then acts as an agonist at the mu-opioid receptors located throughout the central nervous system (CNS). Receptor binding initiates a signaling cascade that alters signaling within supraspinal and limbic structures involved in processing nociceptive input. This engagement results in the inhibition of afferent signal transmission along ascending pathways and contributes to the hyperpolarization of neurons in regulatory circuits.

Influencing Descending Inhibitory Pathways

This domain, also involving the action of Codeine, focuses on its effect on the brainstem's descending pain modulatory system. By binding to mu-opioid receptors in these regions, it activates descending inhibitory pathways that release neurotransmitters such as serotonin and norepinephrine onto the spinal cord. This pathway effect modifies activity in descending tracts involved in the regulation of spinal cord excitability, shaping the drug’s central effect profile.

Dosage and Administration Information

How to Use Voltaren forte (+Codeine)

This section outlines the administration instructions for the Diclofenac/Codeine combination tablet.

Administration Scope


Route of administration:	Oral route
Dosing schedule:	Use the lowest effective dose for the shortest possible duration. The total daily dose for the Diclofenac component should typically not exceed 150 mg. The total daily dose for the Codeine component should generally not exceed 240 mg to 360 mg.
Timing in relation to meals:	Administration is recommended with or after food to help mitigate gastrointestinal irritation associated with the Diclofenac component.
Preparation requirements:	Tablets must be swallowed whole with liquid; do not crush, break, or chew.
Age-group administration rules:	Older Adults (Geriatric): A reduced dosage is required, initiating with the lowest effective dosage. Pediatric: Contraindicated in children under 12 years for pain relief.
Special procedural conditions:	The minimum time interval between doses must be 6 hours. Treatment duration for acute pain is often limited to 3 days.

Official Use Protocol

This medication is administered on an as-needed basis, adhering to the minimum 6-hour dosing interval and the maximum daily dose limits for both active components. The protocol mandates a time-limited duration, particularly for the Codeine component, often restricting acute use to 3 days. The overall requirement is for treatment to be maintained for the shortest duration possible, with the need for continued use subject to periodic re-evaluation. This structured approach defines the required method (swallowed whole) and intake conditions (with food) necessary for proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Voltaren forte(+Codeine)

This overview describes the landscape of available research, focusing only on the types of studies conducted, the populations investigated, and the outcomes measured, as documented in official and peer-reviewed scientific sources. The findings describe group patterns observed in research and not individual predictions or recommendations.

Evidence for Use in Acute Pain

Research examined the combination's application in acute pain, which involves conditions characterized by episodic or acute changes in physical discomfort, such as pain following minor surgery or trauma-related pain.

The research structure includes short-term Randomized Controlled Trials (RCTs). These studies observed responses over defined time intervals, usually comparing the combination against a placebo or the individual active ingredients. Researchers examined outcomes related to physical discomfort, including patient-reported scores on pain intensity and the amount of Rescue Analgesia needed by participants. Research provides insight into short-term changes in symptoms.

Evidence for Use in Chronic Inflammatory Pain

The combination was studied for conditions marked by functional limitations and fluctuating or episodic manifestations, including osteoarthritis (OA) and rheumatoid arthritis (RA). These are conditions where symptoms may vary in intensity.

The research structure includes Systematic Reviews and Meta-Analyses concerning the research surrounding the use of diclofenac, alongside RCTs that compared the full combination against diclofenac alone in chronic settings. Research monitored outcomes reflecting daily functioning or activity level, such as changes in functional and stiffness scores. Some studies describe patterns where the addition of the Codeine component was associated with documented differences in measurements of pain intensity change when compared to diclofenac monotherapy.

Long-Term Studies and Follow-Up Data

The longest observation periods mainly focus on the Diclofenac component, which studies monitored in relation to chronic symptoms over intermediate-term durations. However, research exploring the sustained clinical contribution of the Codeine component when added to diclofenac for chronic pain management is limited in scope.

Limitations and Research Uncertainty

Research provides insight into short-term changes, but there is limited information for long-term outcomes that address the durability of the combination's effect over many months or years. Follow-up durations were limited in many of the combination-specific studies. Furthermore, evidence quality varies across studies, and the research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Voltaren forte(+Codeine) (FAQ)

Q: Can I split the tablet in half to make the dose smaller?

Official regulatory guidelines specify that the tablets must be swallowed whole with a liquid. The product information instructs users to avoid crushing, breaking, or chewing the tablet. Following these administration instructions is necessary for proper use as defined by the official documentation.

Q: Does the drug cause drowsiness or problems with the liver?

Official product information documents the possibility of certain adverse effects. The opioid component, codeine, is associated with common effects like drowsiness (somnolence). Additionally, diclofenac, the NSAID component, can be associated with liver enzyme elevations and, in rare cases, serious hepatic reactions.

Q: What are the signs of an allergic reaction to this medication?

Regulatory warnings indicate a risk of serious reactions, including anaphylaxis and severe skin reactions. Patients should be alert for any signs of hypersensitivity, such as a sudden skin rash or a worsening of pre-existing skin conditions. Official labels state that if these signs appear, the medication should be discontinued and medical attention should be sought immediately.

Q: Can I stop taking the medicine suddenly if I'm feeling better?

For individuals with physical dependence on the codeine component, abrupt discontinuation is generally advised against in official documentation. Regulatory documentation recommends that any change in dosage, including gradual reduction (tapering), be done under the guidance of a healthcare provider.

How should Voltaren forte(+Codeine) be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines for this combination medicine, which contains an opioid component, govern its storage and disposal primarily to maintain product stability and prevent accidental harm.

Requirement Type	Official Regulatory Statement
Storage Temperature	Store the tablets at a temperature below 30 C or at room temperature (20 C to 25 C).
Environmental Protection	The medicine must be kept in the original package to ensure protection from moisture (Source: MHRA SmPC, TGA PI).
Child Protection	It is mandatory to keep out of the sight and reach of children due to the risk of fatal accidental ingestion from the codeine component (Source: FDA PI).
Disposal	Unused or expired medication should be returned to a pharmacy take-back program. If this option is not readily available, the FDA permits flushing the tablets down the toilet as an immediate safety measure to prevent accidental exposure (Source: FDA Guidelines).